Pharmicell Co., Ltd. (005690.KS)
- Previous Close
11,370.00 - Open
11,240.00 - Bid 10,970.00 x --
- Ask 10,980.00 x --
- Day's Range
10,930.00 - 11,560.00 - 52 Week Range
4,300.00 - 12,920.00 - Volume
605,657 - Avg. Volume
1,219,744 - Market Cap (intraday)
655.844B - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield 20.00 (0.18%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease; and Cellgram_AKI for the treatment of acute kidney disease. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs. Further, it operates Twelve, a stem cell bank; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
www.pharmicell.comRecent News: 005690.KS
View MorePerformance Overview: 005690.KS
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 005690.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 005690.KS
View MoreValuation Measures
Market Cap
682.25B
Enterprise Value
671.47B
Trailing P/E
42.11
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.42
Price/Book (mrq)
7.28
Enterprise Value/Revenue
8.30
Enterprise Value/EBITDA
33.84
Financial Highlights
Profitability and Income Statement
Profit Margin
-111.85%
Return on Assets (ttm)
-4.98%
Return on Equity (ttm)
-29.25%
Revenue (ttm)
23.94B
Net Income Avi to Common (ttm)
-26.78B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
9.44B
Total Debt/Equity (mrq)
13.94%
Levered Free Cash Flow (ttm)
-5.79B